Tobacco smoking after diagnosis of cancer: clinical aspects
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Tobacco smoking accounts for at least 30% of all cancer deaths and nearly 90% of lung cancer deaths. Smoking cessation significantly reduces the risk of developing tobacco-related malignancies. Smoking after cancer diagnosis is also associated with multiple risks, including worse tolerance of treatment, higher risk of a failure and second primary tumors, and poorer quality of life. Apart from disease site and stage, continued smoking is considered the strongest adverse predictor of survival in cancer patients. However, the benefits of smoking cessation are undervalued: many patients are not aware of harms related to continued tobacco use after cancer diagnosis. Furthermore, health care professionals often do not encourage their patients to quit, and do not provide tobacco cessation assistance for continuing tobacco users. Despite the apparent impact of tobacco use on treatment outcomes, data on current smoking status is only rarely captured in clinical trials This article reviews the most important clinical aspects of smoking after the diagnosis of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · cited 1×
“Lung cancer patients who continue smoking exhibit higher clearance of erlotinib and gefitinib than nonsmokers (epidermal growth factor receptor inhibitors) and may require higher doses of both compounds to reach equivalent systemic exposure (74-80).”
BackgroundParsons, A., Daley, A., Begh, R., & Aveyard, P. (2010) · BMJ · doi:10.1136/bmj.b5569 · Cited by 696
Sørensen, L. T. (2012) · Archives of Surgery · doi:10.1001/archsurg.2012.5 · Cited by 645 · cited 1×
“49), whereas 4 to 8 weeks of preoperative abstinence from smoking significantly reduced surgical site infections (55).”
BackgroundInfluence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer
Browman, G. P., Wong, G., Hodson, I., Sathya, J., Russell, R., McAlpine, L., Skingley, P., & Levine, M. N. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280302 · Cited by 600 · cited 2×
“Patients with head and neck cancer who continue smoking have lower rates of complete response to radiation therapy and poorer survival, compared to nonsmokers and those who quit prior to treatment (62,63).”
BackgroundEffects of smoking on the pharmacokinetics of erlotinib
Hamilton, M., Wolf, J. L., Rusk, J., Beard, S. E., Clark, G. M., Witt, K., & Cagnoni, P. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2235 · Cited by 312
Smoking at diagnosis and survival in cancer patients
Warren, G. W., Kasza, K. A., Reid, M. E., Cummings, K. M., & Marshall, J. R. (2013) · International Journal of Cancer · doi:10.1002/ijc.27617 · Cited by 265 · cited 2×
“(3), the overall mortality rate among all cancer patients who continued smoking was 20% higher, compared with those who stopped smoking within one year before diagnosis.”
BackgroundEifel, P. J., Jhingran, A., Bodurka, D. C., Levenback, C., & Thames, H. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.128 · Cited by 201 · cited 1×
“(65) including cervical cancer patients managed with radiotherapy, heavy smoking was the strongest independent predictor of overall complications (HR 2.”
BackgroundSmoking relapse during the first year after treatment for early-stage non-small-cell lung cancer
Walker, M. S., Vidrine, D. J., Gritz, E. R., Larsen, R. J., Yan, Y., Govindan, R., & Fisher, E. B. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0509 · Cited by 147 · cited 2×
“Indeed, smoking rates reported by patients are apparently lower than those based on cotinine level verification (26,27).”
BackgroundHughes, A. N., O'Brien, M. E. R., Petty, W. J., Chick, J. B., Rankin, E., Woll, P. J., Dunlop, D., Nicolson, M., Boinpally, R., Wolf, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3995 · Cited by 144 · cited 1×
“(81) showed that pharmacokinetic and toxicity profiles for smokers receiving erlotinib at a 300 mg daily dose is similar to that in nonsmokers receiving 150 mg daily.”
BackgroundCigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.
van der Bol, J. M., Mathijssen, R. H. J., Loos, W. J., Friberg, L. E., van Schaik, R. H. N., de Jonge, M. J. A., Planting, A. S. T., Verweij, J., Sparreboom, A., & de Jong, F. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6115 · Cited by 128
Smoking cessation and lung cancer resection
Dresler, C. M., Bailey, M., Roper, C. R., Patterson, G. A., & Cooper, J. D. (1996) · Chest · doi:10.1378/chest.110.5.1199 · Cited by 119 · cited 1×
“For example, the proportion of lung cancer patients who restart cigarette smoking after treatment ranges between 13% and 60% (23,26,28,36).”
BackgroundTseng, T.-S., Lin, H.-Y., Moody-Thomas, S., Martin, M., & Chen, T. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-784 · Cited by 110
Tabuchi, T., Ito, Y., Ioka, A., Nakayama, T., Miyashiro, I., & Tsukuma, H. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt279 · Cited by 91
Burris, J. L., Studts, J. L., DeRosa, A. P., & Ostroff, J. S. (2015) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0257 · Cited by 90 · cited 1×
“01 The self-reported prevalence of smoking among cancer survivors ranges in particular studies between 9% and 33% (17-24).”
BackgroundCigarette smoking and survival after ovarian cancer diagnosis
Nagle, C. M., Bain, C. J., & Webb, P. M. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0592 · Cited by 31 · cited 1×
“01 endometrial, and ovarian cancer (95-100).”
Cited by
Xu, L., Sanders, L., Li, K., & Chow, J. C. L. (2021) · JMIR Cancer · doi:10.2196/27850 · Cited by 571
“Smoking accounts for at least 30% of all cancer deaths; however, up to 50% of survivors continue to smoke [88].”
Metadata
- Authors
- Jassem, J.
- Venue
- Translational Lung Cancer Research
- Publisher
- AME Publishing Company
- Published
- 2019-05
- Volume
- 8
- Issue
- S1
- Pages
- S50-S58
- ISSN
- 2218-6751 (ISSN-L)
- 2226-4477
- OpenAlex
- W2945996531
- Cited by
- 164
- References
- 15
- FWCI
- 9.86
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.